The Latin America, Middle East and Africa Sclerotherapy Market is expected to witness market growth of 8.8% CAGR during the forecast period (2020-2026).
A foam with detergent sclerosants allows a more efficient sclerosant effect by increasing both dwell time and contact area while minimizing the admixture of sclerosant and blood. This increase in efficiency allows lower sclerosants doses. Ultrasound-guided foam sclerotherapy is an upcoming therapy which allows the doctor to monitor the effect of each injection while ensuring the safety of all adjacent structures and effective is more effective as compared to a liquid therapy.
The market has become highly competitive in nature. One of the key factors that is leading to the competitiveness among market players include rapid adoption of advanced technologies such as ultrasound-guided sclerotherapy, and foam therapy. Furthermore, a conspicuous number of these players are swiftly opting for collaborations and strategic expansions for growing their geographical presence and increasing sales volume in evolving and economically encouraging regions.
In the current scenario, more respected hospital is preferring to opt for minimally invasive surgical procedure including Sclerotherapy Treatment. Sclerosing agents that are used for the varicose veins treatment is segmented into detergents, chemical irritants, and hyperosmolar/ osmotic agents.
Based on Agent, the market is segmented into Detergents, Osmotic Agents and Chemical Irritants. Based on Type, the market is segmented into Liquid Sclerotherapy, Ultrasound Sclerotherapy and Foam Sclerotherapy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, Perrigo Company PLC (Omega Pharmaceuticals), Cook Medical, Inc. (Cook Group), Chemische Fabrik Kreussler & Co. GmbH, LGM Pharma, LLC, Troikaa Pharmaceuticals Limited, Tianyu Chang’an Group, Endo-Flex GmbH (Meditek Systems), Merz Pharma GmbH & Co. KGaA, and MTW-Endoskopie W. Haag KG.
Scope of the Study
Market Segmentation:
By Agent
By Type
By Country
Companies Profiled
Unique Offerings from the Publisher
A foam with detergent sclerosants allows a more efficient sclerosant effect by increasing both dwell time and contact area while minimizing the admixture of sclerosant and blood. This increase in efficiency allows lower sclerosants doses. Ultrasound-guided foam sclerotherapy is an upcoming therapy which allows the doctor to monitor the effect of each injection while ensuring the safety of all adjacent structures and effective is more effective as compared to a liquid therapy.
The market has become highly competitive in nature. One of the key factors that is leading to the competitiveness among market players include rapid adoption of advanced technologies such as ultrasound-guided sclerotherapy, and foam therapy. Furthermore, a conspicuous number of these players are swiftly opting for collaborations and strategic expansions for growing their geographical presence and increasing sales volume in evolving and economically encouraging regions.
In the current scenario, more respected hospital is preferring to opt for minimally invasive surgical procedure including Sclerotherapy Treatment. Sclerosing agents that are used for the varicose veins treatment is segmented into detergents, chemical irritants, and hyperosmolar/ osmotic agents.
Based on Agent, the market is segmented into Detergents, Osmotic Agents and Chemical Irritants. Based on Type, the market is segmented into Liquid Sclerotherapy, Ultrasound Sclerotherapy and Foam Sclerotherapy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, Perrigo Company PLC (Omega Pharmaceuticals), Cook Medical, Inc. (Cook Group), Chemische Fabrik Kreussler & Co. GmbH, LGM Pharma, LLC, Troikaa Pharmaceuticals Limited, Tianyu Chang’an Group, Endo-Flex GmbH (Meditek Systems), Merz Pharma GmbH & Co. KGaA, and MTW-Endoskopie W. Haag KG.
Scope of the Study
Market Segmentation:
By Agent
- Detergents
- Osmotic Agents
- Chemical Irritants
By Type
- Liquid Sclerotherapy
- Ultrasound Sclerotherapy
- Foam Sclerotherapy
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Boston Scientific Corporation
- Perrigo Company PLC (Omega Pharmaceuticals)
- Cook Medical, Inc. (Cook Group)
- Chemische Fabrik Kreussler & Co. GmbH
- LGM Pharma, LLC
- Troikaa Pharmaceuticals Limited
- Tianyu Chang’an Group
- Endo-Flex GmbH (Meditek Systems)
- Merz Pharma GmbH & Co. KGaA
- MTW-Endoskopie W. Haag KG
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Sclerotherapy Market by Agent
Chapter 4. LAMEA Sclerotherapy Market by Type
Chapter 5. LAMEA Sclerotherapy Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Boston Scientific Corporation
- Perrigo Company PLC (Omega Pharmaceuticals)
- Cook Medical, Inc. (Cook Group)
- Chemische Fabrik Kreussler & Co. GmbH
- LGM Pharma, LLC
- Troikaa Pharmaceuticals Limited
- Tianyu Chang’an Group
- Endo-Flex GmbH (Meditek Systems)
- Merz Pharma GmbH & Co. KGaA
- MTW-Endoskopie W. Haag KG
Methodology
LOADING...
